Materials and Methods

Patient cell lines
Cell lines were used from several patients suffering from various peroxisomal and mitochondrial fatty acid β-oxidation disorders. The patients with a PBD all had the clinical and biochemical abnormalities described for PBD patients, including deficient C26:0 and pristanic acid β-oxidation and phytanic acid α-oxidation, and the absence of peroxisomes as assessed by immunofluorescence microscopy analysis using antibodies against catalase (18) .
The fibroblasts from the X-ALD patient had impaired C26:0 β-oxidation, which is caused by a mutation in the gene encoding the peroxisomal membrane protein ALDP (19) . The SCOXand DBP-deficient patients all had mutations in the encoding gene and no enzyme activity could be measured in fibroblasts of these patients (20, 21) . Peroxisomes from the patient with RCDP type 1 we studied in this paper, lack 3-ketoacyl-CoA thiolase due to a mutation in the PEX7 gene encoding the PTS2 receptor. Immunoblot studies performed with an antibody raised against 3-ketoacyl-CoA thiolase revealed that only the unprocessed protein of 44 kDa is present in fibroblast homogenates. It is known that 3-ketoacyl-CoA thiolase is synthesized as a precursor protein and is proteolytically cleaved to its mature form of 41 kDa inside the peroxisome (22). The fibroblasts from patients with a mitochondrial β-oxidation disorder used in this study were from patients with a confirmed deficiency of CPT I, CACT, CPT II, VLCAD or MTP due to mutations in the encoding genes (see (17) for review). These 7 were derived from patients diagnosed in this center. Informed consent was obtained from parents or guardians of the patients whose fibroblasts were studied in this paper.
Synthesis of [16- 14 C]16DCA [16- 14 C]16DCA acid was prepared from 15-hydroxypentadecanoic acid (Sigma-Aldrich
Chemie BV, Zwijndrecht, the Netherlands) by a one-carbon elongation procedure at C15. To enhance solubility and protect the carboxylgroup, 15-hydroxypentadecanoic acid was first converted to its corresponding methylester with 2 equivalents of (trimethylsilyl)diazomethane in hexane:methanol 3:1 (v/v). 
Analysis of C16DCA oxidation products in cultured skin fibroblasts
Incubations were carried out at 37°C in minimal essential medium (MEM) supplemented with penicillin/streptomycin, containing 0.4% bovine serum albumin, 400 µM of L-carnitine and 300 µM C16DCA as substrate. Parallel incubations were performed to determine the amount of protein. After 96 h of incubation the culture medium was removed and lipids were extracted for analysis. To 100 µl of medium, 10 µl C7DCA (500 µM) and 20 µl of a mixture of fatty acids (100 µM C9, C13, C17 and C23) were added as internal standards. One ml of acetonitril:37% hydrochloric acid (23:1, v/v) was added to each sample and hydrolysis was allowed to proceed for 2 h at 90°C. After cooling to room temperature, 1 ml of saturated NaCl solution was added and the lipids were extracted twice with 2 ml ether:ethylacetate (1:1, v/v).
The combined organic layers were dried with a small amount of Na 2 SO 4 and centrifuged for 10 min at 1,600 × g to remove the Na 2 SO 4 . The organic phase was taken to dryness under a stream of nitrogen and the residue was resuspended in 100 µl of chloroform. 
Disruption of the FOX2 gene
The fox2∆ deletion mutant was generated by one-step PCR-mediated gene disruption using 
Expression of human recombinant LBP and DBP
The construction of the plasmid for the expression of human DBP in yeast has been described (27) . The coding sequence of human LBP cDNA was amplified by PCR using cloning primers (BamHI-LBP-F 5'-CGA TGG ATC CAT GGC CGA GTA TAC GCG GCT GC-3'
and 
Results
Oxidation of (Table 1) .
Analysis of C16DCA oxidation products in cultured skin fibroblasts
Cultured skin fibroblasts were incubated with C16DCA to study the formation of partial oxidation products, which are not detected as acid-soluble radiolabeled products in the β-oxidation measurements described above if β-oxidation occurs at the unlabeled C-1 end of the DCA. After a 96-h incubation of control human skin fibroblasts formation of C14DCA and C12DCA was observed (see Fig. 3 ). Fibroblasts from a patient with a CACT deficiency also formed C14DCA and C12DCA in similar amounts as the control fibroblasts, however, fibroblasts from PBD patients revealed hardly any formation of C14DCA and C12DCA (Fig.   3 ). (Fig. 4) . For comparison, these parameters were also determined for C16:1-CoA. The apparent K m of LBP was 10.4 µM and the apparent K m of DBP for this substrate was 12.8 µM (Fig. 4) . The measurements with C16:1-CoA were performed in the presence of 10 µM albumin, because in the absence of albumin enzyme activity was inhibited with increasing substrate concentrations, which is a known phenomenon especially for C16-CoA (30) . For this reason, the kinetic parameters for C16:1DC-CoA and C16:1-CoA cannot be compared directly.
Discussion
Although many studies about the site of degradation of DCAs have been published in the past years, the role of peroxisomes and mitochondria in this process has remained unclear and is therefore still subject of discussion. Many different experimental set-ups have been used to obtain a definite answer and to get insight into why both patients with a peroxisomal and patients with a mitochondrial fatty acid oxidation defect have dicarboxylic aciduria. The CACT, CPT II, VLCAD or MTP). In addition, normal formation of the partial oxidation products C14DCA and C12DCA was found after incubation of fibroblasts from a CACTdeficient patient with C16DCA compared to control fibroblasts, whereas hardly any C14DCA
and C12DCA was formed in fibroblasts from PBD patients. These results are in good agreement with the recent identification of hexadecanedioyl-and octadecanedioyl-carnitine in plasma of PBD patients by tandem mass spectrometry (11) and the excretion of C16DCA in urine of PBD patients (9). The small residual activity found could be either mitochondrial or result from peroxisomal enzymes mislocalized in the cytosol.
Our results support the hypothesis that long-chain DCAs are shortened in the peroxisome and that the shortened products are either excreted in the urine or move to the mitochondrion where they can be β-oxidized to completion (2, 4) . The mitochondrial β-oxidation system itself is most likely capable of oxidizing DC-CoAs, although the affinity is much lower than for monocarboxylic CoA esters. DC-CoAs are, however, very poor substrates for CPT I and therefore long-chain DCAs do not enter the mitochondrion (5). Medium-or short-chain DCAs produced from longer-chain DCAs in peroxisomes may be converted to carnitine esters by the peroxisomal carnitine octanoyltransferase (COT) or carnitine acetyltransferase (CAT) and therefore do not need CPT I to enter the mitochondrion. Alternatively, they might not need the mitochondrial carnitine shuttle at all because they are able to enter the mitochondrion as free fatty acids. This hypothesis is also in agreement with medium-chain dicarboxylic aciduria in patients with a mitochondrial fatty acid oxidation defect (10). In light of this hypothesis, however, the finding of such a medium-chain dicarboxylic aciduria in PBD patients is unexpected, but can perhaps be explained by mitochondrial abnormalities described in these patients.
Because our results revealed that peroxisomal β-oxidation is essential for the degradation of C16DCA, we wanted to know which peroxisomal β-oxidation enzymes are involved in this process. Current evidence holds that oxidation of the straight-chain fatty acids, C24:0 and C26:0, involves SCOX, DBP and both 3-ketoacyl-CoA thiolase and SCPx, whereas oxidation of the branched-chain fatty acids, pristanic acid and the bile acid intermediates, involves BCOX, DBP and SCPx. The function of the second multifunctional protein, LBP, is still unknown (12) . Our measurements in fibroblasts from patients with a single peroxisomal enzyme deficiency showed that SCOX is the acyl-CoA oxidase involved in the β-oxidation of C16DCA, because a strongly reduced rate of [16- 14 C]16DCA β-oxidation was found in fibroblasts of patients with SCOX deficiency. Since no SCOX protein can be detected when performing immunoblot analysis in any of the SCOX-deficient cell lines used in this study, it
is not likely that the deficient SCOX protein is responsible for the residual activity. This suggests that either the mitochondrial β-oxidation system is responsible for this residual activity as in fibroblasts of PBD patients, or that the other peroxisomal oxidase, BCOX, can also handle this substrate, but that its activity is not sufficient for normal β-oxidation of [16- 14 C]16DCA. The latter hypothesis is supported by enzymatic studies with purified peroxisomal oxidases. Van Veldhoven et al. (31) showed that in rat liver palmitoyl-CoA oxidase (corresponding to human SCOX) is responsible for 70% of the oxidase activity with C16DC-CoA, while pristanoyl-CoA oxidase was responsible for the remaining 30%. It is very important for the interpretation of these results, however, to keep in mind that in man only one oxidase is present which handles all branched-chain substrates, whereas in rats both a pristanoyl-CoA oxidase and a trihydroxycoprostanoyl-CoA oxidase is present (32) .
In case of the second and third step of the β-oxidation of long-chain DCAs, our measurements in fibroblasts of DBP-deficient patients revealed that LBP is not only able to handle this substrate but can maintain normal β-oxidation in case of a DBP deficiency. This was also demonstrated in the study of Rizzo et al. (11) by the normal amounts of hexadecanedioyl-and octadecanedioyl-carnitine in plasma of a DBP patient, whereas increased levels of these metabolites were identified in plasma of PBD patients. Because this is the first indication of a function for LBP -all other known peroxisomal substrates including very long-chain fatty acids (12), branched-chain fatty acids (12) , the precursor of docosahexaenoic acid (24:6n-3) (33, 34) and leukotrienes (35) , are handled by DBP -we set out to further investigate the role of LBP in the metabolism of C16DCA. Because no patients with LBP deficiency have been identified, we could not perform similar β-oxidation experiments to establish the role of LBP.
To resolve this problem, we expressed human LBP and DBP separately in the S. cerevisiae fox2∆ deletion mutant to enable direct enzyme measurements with C16:1DC-CoA as substrate. Our results show that both LBP and DBP are active with C16:1DC-CoA and have comparable affinities for this substrate (LBP had an apparent K m of 0.3 µM and DBP an apparent K m of 0.9 µM (Fig. 4) ). In addition, for comparison we performed measurements with C16:1-CoA as substrate and found that also for this substrate LBP and DBP have comparable affinities. These results strongly suggest that both LBP and DBP are involved in oxidation of long-chain DCAs since they can handle C16:1DC-CoA equally well and that in case of a deficiency of DBP, LBP can take over its function. The contribution of both enzymes to the oxidation of C16DCA depends most likely on the content of LBP and DBP, respectively, in different tissues, which has been shown to differ (36) . It would be interesting to study whether DBP can also take over the function of LBP completely by investigating whether the LBP knockout mouse (37) accumulates hexadecanedioyl-carnitine in plasma.
Our measurements in fibroblasts of a patient with RCDP type I have shown that the presence of the classical peroxisomal 3-ketothiolase is not crucial for normal β-oxidation of [16- chain fatty acids, does not appear to be involved in degradation of long-chain DCAs, because we found normal oxidation of C]16DCA in an XALD patient.
In conclusion, our results show that C16DCA is primarily oxidized in the peroxisome by the sequential action of SCOX, both LBP and DBP, and SCPx, possibly together with the classical 3-ketothiolase (Fig. 5) . 
